News | Brachytherapy Systems | January 05, 2017

Analysis Shows IORT Boost Effective Prior to Whole Breast Radiation

Results show low morbidity, excellent-to-good cosmetic results and low-grade adverse events for patients with early-stage breast cancer

iCAD, IORT boost, Xoft Axxent Electronic Brachytherapy System, intraoperative radiation therapy, whole breast radiation, early-stage breast cancer, SABCS 2016

January 5, 2017 — iCAD Inc. announced that researchers presented updated data on the use of intraoperative radiation therapy (IORT) with the Xoft Axxent Electronic Brachytherapy (eBx) System during the San Antonio Breast Cancer Symposium (SABCS), Dec. 6-10 in San Antonio, Texas. The data include results from a subset of patients who received IORT with the Xoft System as a boost prior to administration of whole breast radiation therapy (WBRT) in patients with early-stage breast cancer.

At the meeting, research was presented by Alam M. Nisar Syed, M.D., medical director, radiation oncology and endocurietherapy, Memorial Care Cancer Institute, Long Beach Memorial Medical Center. Syed’s findings include updated data on the treatment of 898 patients with early-stage breast cancer using IORT with the Xoft System at 26 hospitals in the United States and Portugal. The findings show that 90 percent of patients had excellent-to-good cosmesis with low rates of high-grade adverse events and recurrences two years post-treatment with Xoft IORT.

Of these 898 patients, 44 presented additional risk factors and were subsequently treated with WBRT, thus receiving an IORT boost dose prior to conventional treatment. This subset of patients was reviewed independently from the primary study, and Syed said he will continue to follow them as a separate subset for the duration of the 10-year study. The findings thus far show that IORT using the Xoft System as a tumor-bed boost at the time of lumpectomy is safe, with low morbidity, excellent-to-good cosmetic results and mostly low-grade adverse events.

“By identifying a subset of boost patients, our multi-center study not only showed positive clinical results, it highlighted the Xoft System’s versatility in the treatment of early-stage breast cancer,” said Syed. “IORT with the Xoft System offers patients many advantages, whether administered as monotherapy for smaller tumors or as a boost for women who require further treatment due to additional risk factors.”

For more information: www.xoftinc.com

Related Content

A patient prepares to have a tomosynthesis-guided prone breast biopsy using the Hologic Affirm prone biopsy system.

A patient prepares to have a tomosynthesis-guided prone breast biopsy using the Hologic Affirm prone biopsy system.

Feature | Breast Biopsy Systems | October 17, 2019 | By Harriet Borofsky, M.D.
The current body of research supporting digital breast tomosynthesis (DBT or 3-D mammography) is now overwhelming, wi
Feature | Breast Imaging | October 16, 2019 | By Jeff Zagoudis
On Jan. 1, 2017, the U.S.
Videos | Radiation Oncology | October 11, 2019
Lorraine Drapek, DNP, nurse practitioner, radiation oncology, GI service,...
Genia Sutton, intGenia Sutton, interim director of radiology

Genia Sutton, interim director of radiology, has seen the benefit to patients. “Five minutes is a lot of time if you are thinking you may have breast cancer,” she said. “Now, technologists aren’t as rushed. They can give a more personal touch because they can spend more time with their patients.”

Sponsored Content | Case Study | Mammography | October 10, 2019
When Cullman Regional Medical Center in Alabama decided to
Patient Treatments With ViewRay's MRIdian Linac Begin in New England
News | Image Guided Radiation Therapy (IGRT) | October 08, 2019
ViewRay Inc. announced today that patient treatments are scheduled to begin in Boston with ViewRay's MRIdian Linac...
Hologic, Inc.’s Company’s Chairman, President and Chief Executive Officer Steve MacMillan, joined a number of employees to ring the Nasdaq Opening Bell for the 14th consecutive year on Oct. 2
News | Women's Health | October 04, 2019
Hologic, Inc.’s Company’s Chairman, President and Chief Executive Officer ...
Breast cancer awareness month is October
News | Clinical Case Studies | October 03, 2019
A decades-long decline in the breast cancer death rate continues, but has begun to slow in recent years, while breast
Volpara's breast density scale

Levels of breast density.

News | Women's Health | October 01, 2019
Celebrating its 10th Anniversary in 2019,...
Videos | Prostate Cancer | September 30, 2019
Bill Hartsell, M.D., medical director of the Northwestern Medicine Proton Center in Warrenville, Ill., discusses the